Statins and outcomes in patients with pneumonia

doi:10.1136/bmj.39038.509167.1F

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Not only healthy user bias

Eric M Mortensen (mortensene@uthscsa.edu),
Marcos I Restrepo, assistant professor of medicine,
Laurel A Copeland, assistant professor of psychiatry,
Mary Jo V Pugh, assistant professor of medicine,
Antonio Anzueto, professor of medicine

¹University of Texas Health Science Center at San Antonio, 7400 Merton Minter Boulevard (11C6), San Antonio, TX 78229, USA

We read with interest the article on the use of statins for patients with pneumonia.1 Although an important addition to the literature, several issues limit this article's usefulness.

The choice of an outcome measure combining in-hospital mortality and admission to intensive care is curious for a prospective study with such a rich clinical database. Previous research shows that 30 day mortality …